EDMONTON, Jan. 30 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced results ...
EDMONTON, April 30 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), today announced that the University of Alberta, a major shareholder of the Company, has ...
EDMONTON, AB, May 3 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), today announced its updated corporate strategy. The Company's new strategy will encompass ...
Positive interim review from Phase II/III trial in secondary progressive multiple sclerosis triggered the payment. BioMS Medical received $10 million from Eli Lilly as a result of positive initial ...
TORONTO, Dec 18 (Reuters) - Shares of BioMS Medical Corp climbed more than 50 percent on Tuesday after the small Canadian biotechnology company signed a global licensing and development agreement with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results